Skip to main content

Table 1 Demographics and baseline characteristics

From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

Characteristics All Patients (N = 30)
Median age (range), years 63.0 (45.0–83.0)
Sex, n (%)
 Male 19 (63)
 Female 11 (37)
Race, n (%)
 White 27 (90)
 Black 2 (7)
 Unknown 1 (3)
Primary tumor type, n (%)
 Colorectal cancer 13 (43)
 Head and neck cancer 10 (33)
 Urothelial transitional cell carcinoma 4 (13)
 Non–small-cell lung cancer 2 (7)
 Melanoma 1 (3)
ECOG performance status, n (%)
 0 9 (30)
 1 19 (63)
 2 2 (7)
Prior lines of therapy, n (%)
 1 4 (13)
 2 3 (10)
  ≥ 3 23 (77)
  1. ECOG Eastern Cooperative Oncology Group